Prevalence of suspected obesity hypoventilation syndrome in Hungarian Intensive Care Units during the COVID‐19 pandemic

Abstract

AbstractIntroductionThe symptoms of obesity hypoventilation syndrome (OHS) may be present for years with concomitant progressive comorbidities, and the condition is frequently diagnosed late as a result of acute‐on‐chronic hypercapnic respiratory failure. Although some data exist on intensive care unit (ICU) prevalence, mortality and morbidity of OHS, little is known about the ICU mortality of these chronic respiratory failure patients during the COVID‐19 pandemic.MethodsWe performed a cross‐sectional observational study in five Hungarian Intensive Care Units for 4 months during the COVID‐19 pandemic. All ICU patients were screened for OHS risk factors by treating physicians. Risk factors were defined as obesity (body mass index [BMI] ≥ 30 kg/m2) and at least one of the following: Epworth Sleepiness Score ≥ 6; symptoms of right heart failure; daytime or night‐time hypoxemia; presence of loud snoring; witnessed apnoea. We calculated prevalence, mortality and factors associated with unfavourable outcome.ResultsA total of 904 ICU patients were screened for OHS risk factors. Overall 79 (8.74 ± 5.53%) patients were reported to have met the criteria for suspected OHS with a mortality rate of 40.5%; 69% (54 patients) of the cohort displayed at least 3 symptoms related to OHS before their acute illness. COVID‐19 infection was associated with higher mortality in OHS‐suspected patients, independently of actual BMI.ConclusionDespite the increased risk of obese patients, suspected OHS did not show higher prevalence than expected during the COVID‐19 pandemic in critically ill patients. COVID‐19 infection however was a risk for mortality in these patients, independent of actual BMI.